免疫检查点抑制剂毒性预测生物标志物的研究进展

doi:10.3969/j.issn.1006-5725.2023.20.001

实用医学杂志 ›› 2023, Vol. 39 ›› Issue (20): 2561-2565.doi: 10.3969/j.issn.1006-5725.2023.20.001

• 临床新进展 • 下一篇

免疫检查点抑制剂毒性预测生物标志物的研究进展

邓俊,王均,高嫦娥,陈晓,史明霞()

昆明医科大学第一附属医院（昆明 650000 ）

收稿日期:2023-07-11 出版日期:2023-10-25 发布日期:2023-11-15
通讯作者: 史明霞 E-mail:shmxia2002@sina.com
作者简介:史明霞，医学博士，教授。昆明医科大学第一附属医院血液内科主任，博士研究生导师，云岭名医。云南省中青年学术技术带头人，云南省高层次卫生技术人才学科带头人，中华医学会血液学分会第九届全国青年委员，中国抗癌协会血液肿瘤专委会全国青年委员，中国抗癌协会血液肿瘤专委会少见浆细胞病协作组委员，云南省血液病质控中心副主任，中华医学会云南省罕见病分会副主任委员，云南省抗癌协会血液肿瘤专委会副主任委员，云南省干细胞与再生医学协会副理事长，云南省免疫学会血液免疫分会副主任委员，中国医师协会云南省血液科医师分会常委，中华医学会云南省血液学会委员。
基金资助:
国家自然科学基金资助项目(82160547);云南省科技厅-昆明医科大学应用基础研究联合专项资金资助项目(202201AC070524)

Research progress of predictive biomarkers for immune⁃related adverse events

Jun DENG,Jun WANG,Chang′e GAO,Xiao CHEN,Mingxia. SHI()

the First Affiliated Hospital of Kunming Medical colledge，Kunming 650000，China

Received:2023-07-11 Online:2023-10-25 Published:2023-11-15
Contact: Mingxia. SHI E-mail:shmxia2002@sina.com

摘要/Abstract

摘要：

在癌症免疫治疗时代，随着越来越多的临床试验结果公布，免疫检查点抑制剂（ICIs）的适应证也越来越广泛，然而大约40%的患者会经历免疫相关不良事件（irAEs），甚至部分患者出现致命性的irAEs，早期识别irAEs可降低irAEs相关死亡及医疗花费，而生物标志物是早期识别ICIs所致毒性反应的重要指标。本文旨在回顾irAEs预测生物标志物的最新进展，通过其梳理指导进行更方便、快捷的预测因子或预测模型的研究，最终服务于临床工作。

关键词: 免疫检查点抑制剂, 免疫相关不良事件, 预测生物标志物

Abstract:

In the era of cancer immunotherapy， with the release of more clinical trial results， the use of ICIs is more and more widely， but about 40% of these patients will experience irAEs， even some patients with fatal irAEs， early identification of irAEs can reduce irAEs related deaths and medical costs， and biomarkers are an important indicator of early identification of toxic reaction caused by ICIs. We review the latest progress in predicting biomarkers of irAEs， guiding the study of more convenient and fast predictors or predictive models through the combing of biomarkers， ultimately serving clinical work.

Key words: immune-checkpoint inhibitors, immune-related adverse events, predictive biomarkers

中图分类号:

R730.5

邓俊,王均,高嫦娥,陈晓,史明霞. 免疫检查点抑制剂毒性预测生物标志物的研究进展[J]. 实用医学杂志, 2023, 39(20): 2561-2565.

Jun DENG,Jun WANG,Chang′e GAO,Xiao CHEN,Mingxia. SHI. Research progress of predictive biomarkers for immune⁃related adverse events[J]. The Journal of Practical Medicine, 2023, 39(20): 2561-2565.

参考文献 48

1	王燕，庞雅琪，许新华.PD-1/PD-L1基因多态性在非小细胞肺癌中的研究进展［J］.实用医学杂志，2022，38（12）：1470-1474.
2	MUSIC M， IAFOLLA M， SOOSAIPILLAI A，et al. Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry［J］. F1000Res，2020，9：337.
3	LES I， MARTÍNEZ M， NARRO A，et al. Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies［J］. Ann Med，2021，53 （1）：762-769.
4	DE MOEL E C， ROAEMAN E A， KAPITEIJN E H，et al. Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors［J］. Cancer Immunol Res，2019，7 （1）：6-11.
5	ALSERAWAN L， ANGUERA G， ZAMORA ATENZA C，et al. Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events［J］. Int J Mol Sci，2022，23 （20）：12641.
6	NAKAMURA Y， TANAKA R， MARUYAMA H，et al. Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies［J］. Jpn J Clin Oncol，2019，49 （5）：431-437.
7	SUAZO-ZEPEDA E， BOKERN M， VINKE P C，et al. Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer： a systematic review and meta-analysis［J］. Cancer Immunol Immunother，2021，70 （11）：3069-3080.
8	刘剑，李敏菁. 全身免疫炎症指数对非小细胞肺癌免疫检查点抑制剂疗效的预测价值［J］. 实用医学杂志，2022，38（7）：904-908.
9	SUBUDHI S K， APARICIO A， GAO J，et al. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities［J］. Proc Natl Acad Sci U S A，2016，113 （42）：11919-11924.
10	GRANITO A， MURATORI L， LALANNE C，et al. Hepatocellular carcinoma in viral and autoimmune liver diseases： Role of CD4⁺ CD25⁺ Foxp3⁺ regulatory T cells in the immune microenvironment［J］. World J Gastroenterol，2021，27 （22）：2994-3009.
11	ARASANZ H， BOCANEGRA A I， MORILLA I，et al. Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer［J］. Cancers （Basel），2022，14 （16）：3846.
12	MUIR C A， CLIFTON-BLIGH R J， LONG G V，et al. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment［J］. J Clin Endocrinol Metab，2021，106 （9）：e3704-e3713.
13	ISAWA T，TOI Y， SUGAWARA S，et al. Incidence， Clinical Characteristics， and Predictors of Cardiovascular Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors［J］. Oncologist，2022，27 （5）：e410-e419.
14	GONG Z， WANG Y. Immune Checkpoint Inhibitor-Mediated Diarrhea and Colitis： A Clinical Review［J］. JCO Oncol Pract，2020，16 （8）：453-461.
15	HUSAIN B， KIRCHBERGER M C， ERDMANN M，et al. Inflammatory markers in autoimmunity induced by checkpoint inhibitors［J］. J Cancer Res Clin Oncol，2021，147 （6）：1623-1630.
16	SHIMOZAKI K， SUKAWA Y， SATO Y，et al. Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data［J］. Future Oncol，2021，17 （20）：2593-2603.
17	ZHAO L， LI Y， JIANG N，et al. Association of Blood Biochemical Indexes and Antibiotic Exposure With Severe Immune-related Adverse Events in Patients With Advanced Cancers Receiving PD-1 Inhibitors［J］. J Immunother，2022，45 （4）：210-216.
18	TANAKA R， OKIYAMA N， OKUNE M，et al. Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativity［J］. J Dermatol Sci，2017，86 （1）：71-73.
19	CHEN A Y， WOLCHOK J D， BASS A R. TNF in the era of immune checkpoint inhibitors： friend or foe？［J］. Nat Rev Rheumatol，2021，17 （4）：213-223.
20	MONTFORT A， FILLERON T， VIRAZELS M，et al. Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma： First Results of a Phase Ib Clinical Trial［J］. Clin Cancer Res，2021，27 （4）：1037-1047.
21	KANG D H， PARK C K， CHUNG C，et al. Baseline Serum Interleukin-6 Levels Predict the Response of Patients with Advanced Non-small Cell Lung Cancer to PD-1/PD-L1 Inhibitors［J］. Immune Netw，2020，20 （3）：e27.
22	DIMITRIOU F， HOGAN S， MENZIES A M，et al. Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy［J］. Eur J Cancer，2021，157：214-224.
23	HAILEMICHAEL Y， JOHNSON D H， ANDEL-WAHAB N，et al. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity［J］. Cancer Cell，2022，40 （5）：509-523.e6.
24	TARHINI A A， ZAHOOR H， LIN Y，et al. Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma［J］. J Immunother Cancer，2015，3：39.
25	JOHNSON D， PATEL A B， UEMURA M I，et al. IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy［J］. Cancer Immunol Res，2019，7 （6）：860-865.
26	ESFAHANI K， MILLER W H. Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade［J］. N Engl J Med，2017，376 （20）：1989-1991.
27	KURIMOTO C， INABA H， ARIYASU H，et al. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors［J］. Cancer Sci，2020，111 （5）：1468-1477.
28	FRIEDRICH M， POHIN M， JACKSON M A，et al. IL-1-driven stromal-neutrophil interactions define a subset of patients with inflammatory bowel disease that does not respond to therapies［J］. Nat Med，2021，27 （11）：1970-1981.
29	ANDREWS M C， DUONG C P M， GOPALAKRISHNAN V，et al. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade［J］. Nat Med，2021，27 （8）：1432-1441.
30	THOMAS A S， MA W， WANG Y. Ustekinumab for Refractory Colitis Associated with Immune Checkpoint Inhibitors［J］. N Engl J Med，2021，384 （6）：581-583.
31	WANG H， ZHOU F， ZHAO C，et al. Interleukin-10 Is a Promising Marker for Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy［J］. Front Immunol，2022，13：840313.
32	FUJIMURA T， SATO Y， TANITA K，et al. Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab： a pilot study［J］. Oncotarget，2018，9 （21）：15542-15551.
33	BINS S， BASAK E A， El BOUAZZAOUI S，et al. Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients［J］. Br J Cancer，2018，118 （10）：1296-1301.
34	KOBAYASHI M， NUMAKURA K， HATAKEYAMA S，et al. Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism［J］. Genes （Basel），2022，13（7）：1204.
35	ABDEL-WAHAB N， DIAB A， YU R K，et al. Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors［J］. Cancer Immunol Immunother， 2021，70（7）：1939-1949.
36	WÖLFFER M， BATTKE F， SCHULZE M，et al. Biomarkers Associated with Immune-Related Adverse Events under Checkpoint Inhibitors in Metastatic Melanoma［J］. Cancers （Basel），2022，14 （2）：302.
37	JIN Y， CHEN D L， WANG F，et al. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors［J］. Mol Cancer，2020，19 （1）：154.
38	FRIEDLANDER P， WOOD K， WASSMANN K，et al. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab［J］. J Immunother Cancer，2018，6 （1）：90.
39	FINKE D， HECKMANN M B， SALATZKI J，et al. Comparative Transcriptomics of Immune Checkpoint Inhibitor Myocarditis Identifies Guanylate Binding Protein 5 and 6 Dysregulation［J］. Cancers （Basel），2021，13（10）：2498.
40	SHI Y， SHEN M， ZHENG X，et al. ICPis-Induced Autoimmune Polyendocrine Syndrome Type 2： A Review of the Literature and a Protocol for Optimal Management［J］. J Clin Endocrinol Metab，2020，105 （12）：dgaa553.
41	DELIVANIS D A， GUSTAFSON M P， BORNSCLEGL S，et al. Pembrolizumab-Induced Thyroiditis： Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms［J］. J Clin Endocrinol Metab，2017，102（8）：2770-2780.
42	IAFOLLA M A J， YANG C， CHANDRAN V，et al. Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis［J］. JNCI Cancer Spectr，2020，5（1）：pkaa115.
43	MASTROIANNI J， STICKEL N， ANDRLOVA H，et al. miR-146a Controls Immune Response in the Melanoma Microenvironment［J］. Cancer Res，2019，79 （1）：183-195.
44	IVANOVA E， ASADULLINA D， RAKHIMOV R，et al. Exosomal miRNA-146a is downregulated in clear cell renal cell carcinoma patients with severe immune-related adverse events［J］. Noncoding RNA Res，2022，7 （3）：159-163.
45	PANTAZI D， TSELEPIS A D. Cardiovascular toxic effects of antitumor agents： Pathogenetic mechanisms［J］. Thromb Res，2022，213 ：S95-S102.
46	CHAU J， YADAW M， LIU B，et al. Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer［J］. BMC Cancer，2021，21 （1）：808.
47	BERNER F， BOMZE D， LICHTENSTEIGER C，et al. Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade［J］. Sci Immunol，2022，7 （75）：eabn9644.
48	TAHIR S A， GAO J， MIURA Y，et al. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities［J］. Proc Natl Acad Sci U S A，2019，116 （44）：22246-22251.

[1]	丁宇轩,郭沥泞,沈佳怡,王丽君. 放疗联合PD-1抑制剂及酪氨酸激酶抑制剂治疗MSS型结直肠癌肝转移疗效及安全性[J]. 实用医学杂志, 2024, 40(9): 1293-1297.
[2]	孟肖娜,孙旭,刘怀民. 免疫检查点抑制剂相关结肠炎的研究进展[J]. 实用医学杂志, 2024, 40(9): 1314-1319.
[3]	张雨峤,梅伟健. 免疫检查点抑制剂治疗实体瘤的标志性成果[J]. 实用医学杂志, 2024, 40(2): 272-277.
[4]	袁胜芳,王布,项保利,赵建清,沈晶晶,张志华. 外周血循环肿瘤DNA预测晚期非小细胞肺癌免疫治疗疗效及预后价值[J]. 实用医学杂志, 2024, 40(15): 2110-2115.
[5]	梁丹,易颖,黄为福,农先胜. 多靶点小分子酪氨酸激酶抑制剂联合免疫检查点抑制剂治疗标准治疗方案失败后晚期实体瘤患者的效果[J]. 实用医学杂志, 2024, 40(1): 102-107.
[6]	徐璐黄栎有王延花温林春 . PD-1抑制剂联合脑部放疗治疗驱动基因阴性非小细胞肺癌脑转移的疗效及安全性分析 [J]. 实用医学杂志, 2022, 38(24): 3100-3105.
[7]	李思玲商凯黄鸿翔陈丽. 放疗联合免疫治疗在非小细胞肺癌中的研究进展[J]. 实用医学杂志, 2022, 38(23): 3017-3022.
[8]	董佳艺陈斯泽邵丽娟宋明瀚. 嵌合抗原受体T细胞疗法联合免疫调节剂治疗实体瘤研究进展[J]. 实用医学杂志, 2022, 38(21): 2643-2648.
[9]	李代龙王雨珂庞雅琪许新华, . 晚期肝细胞癌免疫检查点抑制剂的临床研究进展 [J]. 实用医学杂志, 2021, 37(6): 821-826.
[10]	易楚繁, 付伟金. 免疫检查点抑制剂在晚期前列腺癌中的治疗进展 Role of immune checkpoint inhibitors in treatment of advanced prostate cancer：A literature review [J]. 实用医学杂志, 2021, 37(12): 1516-1519.
[11]	叶强, 陈小燕. 免疫检查点抑制剂的内分泌毒性及临床应对策略 [J]. 实用医学杂志, 2021, 37(11): 1382-1386.

免疫检查点抑制剂毒性预测生物标志物的研究进展

Research progress of predictive biomarkers for immune⁃related adverse events

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 48

相关文章 11

编辑推荐

Metrics

本文评价